Maculopathy Clinical Trials

9 recruitingLast updated: June 18, 2026

There are 9 actively recruiting maculopathy clinical trials across 10 countries. Studies span Not Applicable, Phase 1, Phase 4. Top locations include Baghdad, Iraq, Beverly Hills, California, United States, Coral Springs, Florida, United States. Updated daily from ClinicalTrials.gov.


Maculopathy Trials at a Glance

9 actively recruiting trials for maculopathy are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Not Applicable with 5 trials, with the heaviest enrollment activity in Baghdad, Beverly Hills, and Coral Springs. Lead sponsors running maculopathy studies include Al-Mustansiriyah University, Cellio Therapeutics Inc, and ASST Fatebenefratelli Sacco.

Browse maculopathy trials by phase

Treatments under study

About Maculopathy Clinical Trials

Looking for clinical trials for Maculopathy? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Maculopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Maculopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Phase 1 Study of C.001 in Retinal Degeneration

Geographic AtrophyAge-Related Macular DegenerationStargardt Disease+1 more
Cellio Therapeutics Inc15 enrolled1 locationNCT07594236
Recruiting
Not Applicable

CRYSTALSIGHT Cohort 2.0

Maculopathy
Tan Tock Seng Hospital60 enrolled1 locationNCT07255859
Recruiting
Not Applicable

High Resolution, High-speed Multimodal Ophthalmic Imaging

HypertensionStrokeDiabetes+12 more
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts1,200 enrolled1 locationNCT04129021
Recruiting
Phase 4

Aflibercept and Bevacizumab for Diabetic Maculopathies

Diabetic Maculopathy
Al-Mustansiriyah University102 enrolled1 locationNCT06850571
Recruiting
Not Applicable

Is Community Based Monitoring of Diabetic Maculopathy and Pre-proliferative Diabetic Retinopathy Safe?

Diabetes MellitusDiabetic RetinopathyDiabetic Maculopathy
Hywel Dda Health Board150 enrolled1 locationNCT06955611
Recruiting
Not Applicable

Stem Cell Ophthalmology Treatment Study II

Age-Related Macular DegenerationRetinitis PigmentosaMacular Degeneration+15 more
MD Stem Cells500 enrolled4 locationsNCT03011541
Recruiting
Not Applicable

Evaluation of NeoRetina Artificial Intelligence Algorithm for the Screening of Diabetic Retinopathy at the CHUM

Diabetic RetinopathyDiabetic Macular EdemaDiabetic Maculopathy
Centre hospitalier de l'Université de Montréal (CHUM)630 enrolled1 locationNCT04699864
Recruiting

Visual Involvement in Giant Cell Arteritis

Retinal ischemiacentral retinal artery occlusionGiant Cell Arteritis+6 more
ASST Fatebenefratelli Sacco762 enrolled1 locationNCT06500728
Recruiting

Retinal regeneration Laser Treatment in Early Age-related Maculopathy

Early Age related Maculopathy
Ellex50 enrolled1 locationACTRN12609001056280